Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430706 | 0.85 | ACHE (0.39) | ACHESYKKITKDRFLT3 | |
| SCHEMBL427677 | 0.83 | ACHE (0.39) | CYP2D6CYP2C9CYP3A4ACHESYK | |
| SCHEMBL425197 | 0.83 | ACHE (0.38) | ACHESYKMETKDRFLT3 | |
| SCHEMBL425829 | 0.80 | ACHE (0.37) | ACHESYKMETPOLBCA12 | |
| SCHEMBL5798773 | 0.80 | ACHE (0.40) | ACHESYKPOLBMAOA | |
| SCHEMBL428800 | 0.78 | FES (0.47) | CYP2D6CYP2C9CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL428801 | 0.78 | FES (0.47) | CYP2D6CYP2C9CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL10197247 | 0.78 | FES (0.47) | CYP2D6CYP2C9CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL430595 | 0.77 | SIGMAR1 (0.39) | ACHESYKPOLBHSP90AA1HSP90AB1 | |
| SCHEMBL430597 | 0.77 | SIGMAR1 (0.39) | ACHESYKPOLBHSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919487-B2 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-05 | — | — | US | claimed |
| US-20060122156-A1 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | US | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-7919487-B2 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20060122156-A1 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2006053109-A1 | HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | CYP2D6 1892/4885CYP2C9 1934/4885CYP1A2 443/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | CYP2D6 4828/4885CYP2C9 4880/4885CYP1A2 4750/4885 |
| US-20060122156-A1 | Heteroaryl compounds | IL2, CCL11, IL4 | CYP2D6 317/4885CYP2C9 449/4885CYP1A2 115/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | CYP2D6 879/4885CYP2C9 322/4885CYP1A2 253/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | CYP2D6 4828/4885CYP2C9 4880/4885CYP1A2 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.